Selected Topics: Toxicology| Volume 57, ISSUE 4, e99-e104, October 2019

Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias



      Ibogaine is a psychoactive indole alkaloid that has been investigated for use as a treatment for opioid addiction. While not commercially available in the United States, it is available via Internet suppliers. Ibogaine use has been associated with significant cardiac and neurologic effects, such as QT-segment prolongation, cardiac dysrhythmias, hallucinations, seizures, and central nervous system depression. We present a case of verified ibogaine exposure with associated QTc prolongation and torsade de pointes with qualitative analysis of the ingested substance, and examine the history, social context, availability, and perceptions of ibogaine's effects and safety.

      Case Report

      A 34-year-old white woman with medical history significant for heroin and cocaine use disorder presented with reported seizures 1 day after ingestion of 2 g ibogaine powder purchased from an Internet supplier. Shortly after ingestion, she experienced hallucinations and was reported by family to have four to five seizure-like episodes, at one point becoming apneic. In the emergency department, she was noted to have QTc prolongation and several episodes of torsade de pointes. Qualitative analysis confirmed the presence of ibogaine in the empty foil packages containing the ingested substance.

      Why Should an Emergency Physician Be Aware of This?

      As increasing numbers of opioid-dependent patients attempt to curtail their substance use disorders, we anticipate a rise in ibogaine exposures, necessitating awareness by front-line clinicians in recognizing and treating a drug exposure that can rapidly become life-threatening.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Maciulaitis R.
        • Kontrimaviciute V.
        • Bressolle F.M.
        • Briedis V.
        Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review.
        Hum Exp Toxicol. 2008; 27: 181-194
        • Glick S.D.
        • Maisonneuve I.M.
        Mechanisms of antiaddictive actions of ibogainea.
        Ann N Y Acad Sci. 1988; 844: 214-226
        • Schenberg E.E.
        • de Castro Comis M.A.
        • Chaves B.R.
        • da Silveira D.X.
        Treating drug dependence with the aid of ibogaine: a retrospective study.
        J Psychopharmacol. 2014; 28: 993-1000
        • Xu Z.
        • Chang L.W.
        • Slikker Jr., W.
        • Ali S.F.
        • Rountree R.L.
        • Scallet A.C.
        A dose-response study of ibogaine-induced neuropathology in the rat cerebellum.
        Toxicol Sci. 2000; 57: 95-101
        • Drug Enforcement Administration
        Controlled substances. DEA Diversion—Controlled Substances, Drug Enforcement Administration.
        • Noller G.E.
        • Frampton C.M.
        • Yazar-Klosinski B.
        Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.
        Am J Drug Alcohol Abuse. 2017; 44: 37-46
      1. Guimarães dos Santos R. Ibogaine in the treatment of alcoholism: a randomized, double-blind, placebo-controlled, escalating-dose, phase 2 trial. Available at: Accessed July 29, 2018.

        • Schep L.J.
        • Slaughter R.J.
        • Galea S.
        • Newcombe D.
        Ibogaine for treating drug dependence. What is a safe dose?.
        Drug Alcohol Depend. 2016; 166: 1-5
        • Winkelman M.
        Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, peyote, ibogaine and ayahuasca.
        Curr Drug Abuse Rev. 2015; 7: 101-116
        • Alper K.R.
        • Lotsof H.S.
        • Kaplan C.D.
        The ibogaine medical subculture.
        J Ethnopharmacol. 2008; 115: 9-24
        • Alper K.R.
        • Stajić M.
        • Gill J.R.
        Fatalities temporally associated with the ingestion of ibogaine.
        J Forensic Sci. 2012; 57: 398-412
        • Glue P.
        • Winter H.
        • Garbe K.
        • et al.
        Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20mg dose of ibogaine in healthy volunteers.
        J Clin Pharmacol. 2015; 55: 680-687
        • Mash D.C.
        • Kovera C.A.
        • Pablo J.
        • et al.
        Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.
        Ann N Y Acad Sci. 2000; 914: 394-401
        • O'Connell C.W.
        • Gerona R.R.
        • Friesen M.W.
        • Ly B.T.
        Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels.
        Am J Emerg Med. 2015; 33 (e5–e6): 985
        • Henstra M.
        • Wong L.
        • Chahbouni A.
        • Swart N.
        • Allaart C.
        • Sombogaard F.
        Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine.
        Clin Toxicol. 2017; 55: 600-602
        • Brown T.
        Ibogaine in the treatment of substance dependence.
        Curr Drug Abuse Rev. 2013; 6: 3-16
        • Helsley S.
        • Dlugos C.A.
        • Pentney R.J.
        • Rabin R.A.
        • Winter J.C.
        Effects of chronic ibogaine treatment on cerebellar Purkinje cells in the rat.
        Brain Res. 1997; 759: 306-308
        • Vlaanderen L.
        • Martial L.C.
        • Franssen E.J.
        • van der Voort P.H.
        • Oosterwerff E.
        • Somsen G.A.
        Cardiac arrest after ibogaine ingestion.
        Clin Toxicol (Phila). 2014; 52: 642-643
        • Hildyard C.
        • Macklin P.
        • Prendergast B.
        • Bashir Y.
        A case of QT prolongation and torsades de pointes caused by ibogaine toxicity.
        J Emerg Med. 2016; 50: e83-e87
        • Asua I.
        Growing menace of ibogaine toxicity.
        Br J Anaesth. 2013; 111: 1029-1030
        • Hoelen D.
        • Spiering W.
        • Valk G.D.
        Long-QT syndrome induced by the antiaddiction drug ibogaine.
        N Engl J Med. 2009; 360: 308-309
        • Brown T.K.
        • Alper K.R.
        Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.
        Am J Drug Alcohol Abuse. 2017; 44: 24-36
        • Koenig X.
        • Kovar M.
        • Boehm S.
        • Sandtner W.
        • Hilber K.
        Anti-addiction drug ibogaine inhibits HERG channels: a cardiac arrhythmia risk.
        Addict Biol. 2012; 19: 237-239
        • Thurner P.
        • Stary-Weinzinger A.
        • Gafar H.
        • et al.
        Mechanism of HERG channel block by the psychoactive indole alkaloid ibogaine.
        J Pharmacol Exp Ther. 2013; 348: 346-358
        • Litjens R.P.W.
        • Tibor B.
        How toxic is ibogaine?.
        Clin Toxicol. 2016; 54: 297-302
        • Alper K.R.
        • Lotsof H.S.
        Treatment of acute opioid withdrawal with ibogaine.
        Am J Addict. 1999; 8: 234-242
        • Nestor J.
        Get clean or die trying.
        Sci Am. 2016; 315: 62-69
        • Delorenzi J.C.
        Phase 2 trial to evaluate 18-methoxycoronaridine efficacy, safety and tolerability in cutaneous leishmaniasis patients.
        Infan Industria Quimica Farmaceutica Nacional, 2018